Experimental drug could help reduce brain damage, improve motor skills after stroke

September 21, 2012 by Alexis Blue, University of Arizona
Ribbon structure of the drug 3K3A-APC, which researchers hope will help reduce brain damage in stroke victims. Credit: ZZ Biotech

(Medical Xpress)—A University of Arizona professor is overseeing the manufacture of an experimental drug that could help reduce brain damage after a stroke.

The drug, known as 3K3A-APC, currently is undergoing clinical trials in Europe to determine its safety in humans after proving effective in animal models at reducing brain damage and improving motor skills after a stroke when given in combination with another commonly used .

Thomas Davis, professor of pharmacology in the UA College of Medicine, was chosen to direct the manufacture of the drug for human trials after co-authoring a recent paper in the journal Stroke that pointed to the drug's effectiveness in rats and mice when used in conjunction with a clot-busting therapy known as , or tPA.

While tPA is commonly given to sufferers of , which results from an obstruction in a blood vessel supplying blood to the brain, the therapy poses significant challenges when administered alone, including a limited treatment window, Davis said.

"It has to be given within the first three to four and a half hours of the stroke," Davis said. "It only works in 10 percent of the patients, and it causes bleeding, so tPA alone isn't that effective."

Researchers now have found that 3K3A-APC, with its cell protective properties, may be effective in extending the treatment window for tPA while protecting against programmed cell death in the brain, which occurs when cellular signals convince to kill themselves following a stroke. When tested in rodents, the reduced by more than half, eliminated tPA-induced bleeding and significantly improved motor abilities.

The drug 3K3A-APC initially was created by a team of scientists at the Scripps Research Institute and the University of Southern California, led by John Griffin, professor at the Scripps Research Institute, and Dr. Berislav V. Zlokovic, director of the Neurogenic Institute at USC's Keck School of Medicine. It was further developed by Houston-based biotech company ZZ Biotech, for which Davis serves as a consultant and member of the scientific board of directors.

Davis worked closely with Griffin, Zlokovic and other collaborators to develop proper manufacturing procedures for the drug, which is being produced under Davis' direction by ZZ Biotech's contracted manufacturer, Laureate Biopharmaceuticals, in New Jersey.

The drug 3K3A-APC is a genetically engineered variant of the naturally occurring activated protein C, or APC, which helps regulate blood clots and inflammation in the body.

Previous research on naturally occurring APC, conducted by Griffin and Zlokovic, pointed to the protein's ability to prevent programmed in the brain. However, APC's natural blood-thinning properties posed a problem when considered as a treatment for stroke, since it might induce bleeding in the brain.

To address that problem, Griffin's hematology lab worked to develop an engineered variant of APC with fewer anticoagulant properties, and thus 3K3A-APC was born.

Davis was chosen to lead the production of the drug because of his extensive drug manufacturing experience and connection to ZZ Biotech.

Prior to joining the UA College of Medicine in 1980, Davis worked as a chemist for Abbot Pharmaceutical Co. Considered a premier investigator in the field of blood brain barrier research, Davis is widely regarded for changing the way drugs are designed and manufactured by pharmaceutical companies for brain delivery.

So far, no side effects have been shown in the initial clinical trials of 3K3A-APC in normal human subjects, Davis said, adding that he is prepared to manufacture more of the drug for future trials. "Starting next January, it will go into phase two clinical trials in patients as an adjuvant therapy, together with ."

Explore further: Experimental drug may extend therapeutic window for stroke

Related Stories

Experimental drug may extend therapeutic window for stroke

July 17, 2012
A team led by a physician-scientist at the University of Southern California (USC) has created an experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally ...

Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech

August 8, 2012
Clinical trials start this week for a stroke drug initially created by a team led by scientists at The Scripps Research Institute and the University of Southern California (USC), and further developed by biotech company ZZ ...

Clot-busting drug safe for stroke patients taking blood thinner

May 10, 2012
Acute ischemic stroke patients taking the blood thinner warfarin can be treated safely with the clot-busting drug tissue plasminogen activator (tPA), according to research presented at the American Heart Association's Quality ...

Hypothermia protects the brain against damage during stroke

March 6, 2012
Thromboembolic stroke, caused by a blood clot in the brain, results in damage to the parts of the brain starved of oxygen. Breaking up the clot with tissue plasminogen activator (tPA) reduces the amount of damage, however, ...

Recommended for you

Anemia discovery offers new targets to treat fatigue in millions

January 22, 2018
A new discovery from the University of Virginia School of Medicine has revealed an unknown clockwork mechanism within the body that controls the creation of oxygen-carrying red blood cells. The finding sheds light on iron-restricted ...

More surprises about blood development—and a possible lead for making lymphocytes

January 22, 2018
Hematopoietic stem cells (HSCs) have long been regarded as the granddaddy of all blood cells. After we are born, these multipotent cells give rise to all our cell lineages: lymphoid, myeloid and erythroid cells. Hematologists ...

How metal scaffolds enhance the bone healing process

January 22, 2018
A new study shows how mechanically optimized constructs known as titanium-mesh scaffolds can optimize bone regeneration. The induction of bone regeneration is of importance when treating large bone defects. As demonstrated ...

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

wealthychef
not rated yet Sep 21, 2012
The article says tPA must be given within 3-4 hours of the stroke, implying APC is superior, but does not say how APC is superior to this if at all.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.